LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Rapid 45-Minute COVID-19 Test Ideal for Screening at Points of Risk

By LabMedica International staff writers
Posted on 09 Jul 2020
Print article
Image: Dr. Laura Lamb (Photo courtesy of Beaumont Research Institute)
Image: Dr. Laura Lamb (Photo courtesy of Beaumont Research Institute)
Researchers at the Aikens Research Center at Beaumont Research Institute (Southfield, MI, USA) who developed the test found the results to be highly accurate as compared to existing technology. Additionally, the rapid test is also relatively inexpensive to develop and operate as the materials for it are inexpensive and it does not require expensive machinery to run.

The researchers adapted the same technology for the COVID-19 test that they had come up with for a rapid, Zika virus detection test about three years ago. The detection test builds on recommendations from Anthony Fauci, M.D., immunologist and director of the National Institute of Allergy and Infectious Diseases since 1984, that rapid testing and tracing are the keys to containing the coronavirus. The researchers are now focusing on securing corporate sponsorship to fund development of the COVID-19 test.

According to Laura Lamb, Ph.D., who led the team, the test “could be used for screening at the point of risk, such as nursing homes, long-term care facilities, cruise ships, naval ships, within the school and prison systems, and by large employers, for example, at an Amazon warehouse or meatpacking plant. Because this is an existing test, we are optimistic with the right resources, it could be ready for widespread use within a month or so.”

Related Links:
Beaumont Research Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more